Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction

ArticleAçık Erişim

Özet

Objective: To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods: A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire- 5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol and total cholesterol were measured. The independentsamples t-test was used to compare the pre- and post-treatment scores of the patients. Results: The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p < 0.01). Conclusion: A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14648Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKarabakan, Mehmet
dc.contributor.authorKeskin, Ercument
dc.contributor.authorAkdemir, Serkan
dc.contributor.authorBozkurt, Aliseydi
dc.date.accessioned2026-10-18T20:29:27.051551446Z
dc.date.available2026-10-18T20:29:27.051551446Z
dc.date.issued2017
dc.description.abstractObjective: To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods: A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire- 5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol and total cholesterol were measured. The independentsamples t-test was used to compare the pre- and post-treatment scores of the patients. Results: The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p < 0.01). Conclusion: A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.
dc.identifier.doi10.1590/s1677-5538.ibju.2016.0376
dc.identifier.eissn1677-6119
dc.identifier.endpage324
dc.identifier.issn1677-5538
dc.identifier.issue2
dc.identifier.pmcidPMC5433372
dc.identifier.pmid27819758
dc.identifier.scopus2-s2.0-85017472672
dc.identifier.startpage317
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14648
dc.identifier.volume43
dc.identifier.wosWOS:000396002900020
dc.language.isoen
dc.publisherBrazilian Society of Urology
dc.relation.ispartofInternational Braz J Urol
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEjaculation
dc.subjectErectile dysfunction
dc.subjectTadalafil
dc.subjectTherapeutics
dc.subjectAdult
dc.subjectAged
dc.subjectBlood Glucose
dc.subjectCholesterol
dc.subjectDrug Administration Schedule
dc.subjectHumans
dc.subjectLower Urinary Tract Symptoms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPenile Erection
dc.subjectPhosphodiesterase 5 Inhibitors
dc.subjectPremature Ejaculation
dc.subjectRetrospective Studies
dc.subjectStatistics, Nonparametric
dc.subjectSurveys and Questionnaires
dc.subjectTestosterone
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.subjectglucose blood level
dc.subjectphosphodiesterase V inhibitor
dc.subjectanalysis
dc.subjectblood
dc.subjectdrug administration
dc.subjectdrug effects
dc.subjecthuman
dc.subjectnonparametric test
dc.titleEffect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus18
rdl.citation.wos16
rdl.departmentDepartment of Urology, Mengucek Gazi Research and Training Hospital, Erzincan University, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)